Insmed
INSM
146 hedge funds and large institutions have $2.3B invested in Insmed in 2017 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 66 increasing their positions, 23 reducing their positions, and 10 closing their positions.
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
330% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 10
187% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 23
137% more capital invested
Capital invested by funds: $970M → $2.3B (+$1.33B)
28% more funds holding
Funds holding: 114 → 146 (+32)
5.04% more ownership
Funds ownership: 91.04% → 96.08% (+5%)
9% more call options, than puts
Call options by funds: $65.6M | Put options by funds: $60.4M
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$48.9M |
| 2 |
BlackRock
New York
|
+$44.1M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$44M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$41.4M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$37.7M |
Top Sellers
| 1 |
O
OrbiMed
New York
|
-$48M |
| 2 |
JP Morgan Chase
New York
|
-$10.4M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$9.24M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$8.04M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$6.53M |
INSM Hedge Fund Activity: Q3 2017 in Review
146 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q3 2017, worth a combined $2.3B — up 137% from $970M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new INSM positions and 10 closed out — a net gain of 33 holders — while 66 added to existing stakes and 23 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $48.9M. The largest seller was OrbiMed, cutting an estimated $48M.
- 146 institutional investors held Insmed (INSM) as of Q3 2017, up from 114 in Q2 2017.
- Funds reported $2.3B of Insmed stock for Q3 2017, up 137% quarter-over-quarter.
- 43 funds opened new Insmed positions in Q3 2017 and 10 closed out, a net change of +33 holders.
- The largest Insmed buyer in Q3 2017 was T. Rowe Price Associates, an estimated $48.9M added.
- The largest Insmed seller in Q3 2017 was OrbiMed, an estimated $48M sold.
Based on aggregated 13F filings for Q3 2017.